Sean A. McCarthy - 13 Jun 2025 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
CEO, Director
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Sean A. McCarthy
Issuer symbol
CTMX
Transactions as of
13 Jun 2025
Net transactions value
-$149,264
Form type
4
Filing time
17 Jun 2025, 16:09:02 UTC
Previous filing
20 Mar 2025
Next filing
30 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
McCarthy Sean A. CEO, Director C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO /s/ Lloyd Rowland, as Attorney-in-Fact for Sean A. McCarthy 17 Jun 2025 0001654058

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Options Exercise $0 +150,000 +15% $0.000000 1,145,195 13 Jun 2025 Direct F1, F2
transaction CTMX Common Stock Sale $149,264 -55,511 -4.8% $2.69 1,089,684 16 Jun 2025 Direct F2, F3
holding CTMX Common Stock 93,158 13 Jun 2025 See footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTMX Performance Stock Units Options Exercise $0 -150,000 -100% $0.000000 0 13 Jun 2025 Common Stock 150,000 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction represents the vesting of performance stock units ("PSUs") initially granted on February 2, 2023.
F2 Includes 488,750 restricted stock units.
F3 The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs.
F4 Shares held by Sean A. McCarthy 2018 Trust, of which the Reporting Person is trustee.
F5 Each PSU represented a contingent right to receive one (1) share of common stock upon vesting.